Recent advances in multinuclear complexes as potential anticancer and DNA binding agents

Anticancer Agents Med Chem. 2014 Jan;14(1):147-69. doi: 10.2174/18715206113139990313.

Abstract

In the search for new metal-based anticancer agents as effective candidates for cisplatin, a lot of strategies such as synthesis of cisplatin analogs, trans-platinum compounds and non-platinum metal complexes have been put forward in the last forty years. The concept of multinuclearity for improving the chemotherapeutic activity has been proven in multinuclear platinum complexes such as BBR3464, recently, the effective approach has been successfully transferred to ruthenium complexes. In this review, we highlighted the recent progress in multinuclear platinum complexes and ruthenium complexes as anticancer agents, and their novel DNA binding properties such as phosphate clamps, long range DNA cross links, bisintercalation, interduplex cross links and DNA-protein cross-links were summarized to shed light on the rational design of polynuclear complexes as anticancer agents.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Antineoplastic Agents / chemistry
  • Antineoplastic Agents / metabolism
  • Antineoplastic Agents / pharmacology*
  • Apoptosis / drug effects
  • Coordination Complexes / chemistry
  • Coordination Complexes / metabolism
  • Coordination Complexes / pharmacology*
  • Cross-Linking Reagents / chemistry
  • Cross-Linking Reagents / metabolism
  • Cross-Linking Reagents / pharmacology
  • DNA / chemistry
  • DNA / metabolism*
  • DNA Adducts / chemistry
  • DNA Adducts / metabolism
  • Humans
  • Intercalating Agents / chemistry
  • Intercalating Agents / metabolism
  • Platinum*
  • Ruthenium*
  • Structure-Activity Relationship

Substances

  • Antineoplastic Agents
  • Coordination Complexes
  • Cross-Linking Reagents
  • DNA Adducts
  • Intercalating Agents
  • Platinum
  • Ruthenium
  • DNA